

Inositol 1,4,5-trisphosphate receptor 1 mutation perturbs glucose homeostasis and enhances susceptibility to diet-induced diabetes

Risheng Ye*, Min Ni[†], Miao Wang*, Shengzhan Luo[‡], Genyuan Zhu, Robert H Chow¹ and Amy S Lee

Department of Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, California 90089-9176, USA

¹Department of Physiology and Biophysics, Zilkha Neurogenetic Institute, University of Southern California Keck School of Medicine, 1501 San Pablo Street, Los Angeles, California, 90089-2821, USA

(Correspondence should be addressed to A S Lee; Email: amylee@ccnt.usc.edu)

*R Ye and M Wang are now at UT Southwestern Medical Center, Dallas, Texas, USA)

[†](M Ni is now at Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts, USA)

[‡](S Luo is now at Janelia Farm Research Campus, Howard Hughes Medical Institute, Ashburn, Virginia, USA)

Abstract

The inositol 1,4,5-trisphosphate receptors (IP3Rs) as ligand-gated Ca^{2+} channels are key modulators of cellular processes. Despite advances in understanding their critical role in regulating neuronal function and cell death, how this family of proteins impact cell metabolism is just emerging. Unexpectedly, a transgenic mouse line (D2D) exhibited progressive glucose intolerance as a result of transgene insertion. Inverse PCR was used to identify the gene disruption in the D2D mice. This led to the discovery that *Itp1* is among the ten loci disrupted in chromosome 6. *Itp1* encodes for IP3R1, the most abundant IP3R isoform in mouse brain and also highly expressed in pancreatic β -cells. To study IP3R1 function in glucose metabolism, we used the *Itp1* heterozygous mutant mice, *opt/+*. Glucose

homeostasis in male mice cohorts was examined by multiple approaches of metabolic phenotyping. Under regular diet, the *opt/+* mice developed glucose intolerance but no insulin resistance. Decrease in second-phase glucose-stimulated blood insulin level was observed in *opt/+* mice, accompanied by reduced β -cell mass and insulin content. Strikingly, when fed with high-fat diet, the *opt/+* mice were more susceptible to the development of hyperglycemia, glucose intolerance, and insulin resistance. Collectively, our studies identify the gene *Itp1* being interrupted in the D2D mice and uncover a novel role of IP3R1 in regulation of *in vivo* glucose homeostasis and development of diet-induced diabetes.

Journal of Endocrinology (2011) **210**, 209–217

Introduction

The inositol 1,4,5-trisphosphate receptors (IP3Rs) are a family of ligand-gated Ca^{2+} channels. Located on the membrane of intracellular Ca^{2+} stores, such as endoplasmic reticulum (ER) and secretory vesicles, IP3Rs mediate Ca^{2+} release when bound with IP3 (Foskett *et al.* 2007). As key modulators of cytosolic Ca^{2+} concentration, IP3Rs have intensively been studied in various Ca^{2+} -controlled cellular processes including muscle contraction, neuronal processing, and cell death (Vanderheyden *et al.* 2009). In the central nervous system, IP3R-mediated Ca^{2+} signaling regulates synaptic transmission, secretion, excitability, learning, and memory (Foskett 2010). Emerging evidence suggests that the IP3Rs may also play regulatory roles in pancreatic β -cell exocytosis and metabolism (Srivastava *et al.* 1999, Dyachok & Gylfe 2004). For example, mice heterozygous for the *anx7* gene, which encodes for Ca^{2+} -activated GTPase supporting Ca^{2+} channel activities, exhibit defects in IP3R expression,

Ca^{2+} signaling, and insulin secretion in cells from pancreatic islets (Srivastava *et al.* 1999). It has been reported that protein kinase A-mediated promotion of Ca^{2+} -induced Ca^{2+} release via IP3Rs is implicated as part of the mechanism by which cAMP amplifies insulin release (Dyachok & Gylfe 2004).

In mammals, there are three isoforms of IP3R (IP3R1, 2, and 3) forming homo or heterotetrameric channels (Foskett *et al.* 2007). Expression of mouse IP3R2 is most prominent in cardiac and skeletal muscle, as well as liver, kidney, and other epithelial tissues, whereas mouse IP3R3 is expressed in both endocrine and exocrine pancreas, as well as testis, spleen, thymus, and gastrointestinal tract (Taylor *et al.* 2009). Strikingly, double knockout of IP3R2 and 3 in mice showed severe impairment of Ca^{2+} signaling and secretion in acinar cells of the exocrine tissues, and the mice are lean and hypoglycemic as a result of difficulty in nutrient digestion (Futatsugi *et al.* 2005). Furthermore, variations within IP3R3 have been identified as a risk factor for type 1 diabetes in humans (Roach *et al.* 2006).

IP3R1 is the most abundant isoform in mouse brain and pancreatic β -cells (De Smedt *et al.* 1997, Lee & Laychock 2001). In mice and humans, genetic mutation and functional impairment of IP3R1 have been linked to multiple neurological diseases, including spinocerebellar ataxias and Huntington's and Alzheimer's diseases (Foskett 2010). The IP3R1 gene (*Itp1*), located on the distal portion of mouse chromosome 6, is critical for survival as its homozygous deletion in mice leads to ataxia and epileptic seizures resulting in death by 3–4 weeks of age (Matsumoto *et al.* 1996). Interestingly, these phenotypes are highly similar to that of the *opisthotonos* (*opt*) mouse (Street *et al.* 1997). The *opt* mutation spontaneously arose in a C57BL/Ks-db2J colony and classic genetic techniques localized *opt* to the same chromosomal localization as *Itp1*. Subsequent genetic and molecular analysis revealed that the *opt* mutation results in a genomic deletion of two exons in *Itp1* and aberrant splicing of the *Itp1* mRNA transcripts (Street *et al.* 1997). Thus, the *opt* mutation leads to production of IP3R1 protein missing several potential kinase and ATP-binding regulatory sites, with decreased stability. In western blot analysis, the IP3R1 protein level was about 10 and 67% of the wild-type level for *opt* homozygotes and heterozygotes respectively (Street *et al.* 1997), likely resulting from protein degradation mediated by cellular protein quality control mechanisms (Foskett 2010).

The GRP78 gene (*Grp78*, also known as *Hspa5*) encodes for a stress-inducible ER chaperone that is a master regulator of the unfolded protein response (UPR; Wang *et al.* 2009). Recent studies showed that *Grp78* heterozygosity triggers adaptive UPR, resulting in attenuation of diet-induced obesity and diabetes in C57BL/6 mice (Ye *et al.* 2010a). Transgenic mouse models are valuable tools for investigating gene expression patterns *in vivo* (Xian *et al.* 2001). While investigating the role of *Grp78* promoter elements in regulating the expression of this gene *in vivo*, we created several transgenic mouse strains with *Grp78* promoter deletions. Fortuitously, we observed progressive glucose intolerance in one of the transgenic mouse lines, referred to below as D2D, as a consequence of the genomic integration site of the transgene. With inverse PCR (IPCR), we determined that the transgene replaced ten loci on chromosome 6, with the *Itp1* gene interrupted near the middle. As a first step toward elucidating the molecular mechanism leading to glucose intolerance in the D2D line, we investigated whether disruption of one *Itp1* allele is a contributing factor to the phenotype, assisted by the *opt/+* mouse model. Our results revealed that *opt/+* mice exhibited glucose intolerance but no insulin resistance. Decrease in second-phase glucose-stimulated blood insulin level was observed in *opt/+* mice, associated with reduction in β -cell mass and insulin content. The pathophysiological significance of IP3R1 heterozygosity was further revealed by the aggravation of high-fat diet (HFD)-induced diabetes in *opt/+* mice. Collectively, our findings demonstrate a novel physiological role of IP3R1 in maintenance of glucose homeostasis.

Materials and Methods

Ethics statement

All protocols for animal use and euthanasia were reviewed and approved by the University of Southern California Institutional Animal Care and Use Committee. The animal assurance number is A3518-01. The protocol numbers are 9964, 10 621, 11 307.

Plasmid construction

To construct the D2/LacZ plasmid, the BamHI fragment from –169/LacZ was first inserted into the BglII site at the internal deletion junction of D300/LacZ (Luo *et al.* 2003). The D2 promoter was then digested with HindIII and subcloned back to the SV40- β -gal plasmid at the HindIII site.

Animals

The D2/LacZ transgenic mouse lines (D2D, D2P, and D2L) were generated by the same procedure as described previously (Dong *et al.* 2004). *Itp1* heterozygous mutant mice *opt/+* were purchased from Jackson Laboratory (Bar Harbor, ME, USA), in the B6C3Fe genetic background. Both D2D and the *opt/+* mice were maintained via sibling mating. Mice were fed on regular diet (RD, 11% fat by calories, Harlan Teklad, Placentia, CA, USA) continuously after weaning at 3 week old, or changed to HFD (45% fat by calories, Research Diets, New Brunswick, NJ, USA) at 10 week old, with food access made available *ad libitum*. Only male mice were used in this study. Mouse body weight was measured after overnight fasting. Food intake was analyzed by daily food mass measurement for 4 or 5 successive days. Mouse stool was processed to Oil Red O staining for lipids as described (Ye *et al.* 2010a). After killing, the epididymal fat pads and liver were removed and weighed and then calculated as percentage of whole body weight.

Blood glucose, insulin, triglyceride, and free fatty acid

Mouse tail blood was measured for glucose by OneTouch Ultra System (Lifescan, Inc., Milpitas, CA, USA), or prepared for plasma and measured for insulin with ELISA kit (Linco Research, Billerica, MA, USA). Retro-orbital blood was collected and prepared for serum, then assayed for triglyceride and free fatty acid by the Mouse Metabolic Phenotyping Core at the University of Texas Southwestern Medical Center.

Glucose tolerance test

After overnight fasting, mice were subjected to i.p. injection of glucose (1 mg/g body weight), followed by blood glucose or insulin measurement at multiple time points.

Insulin tolerance test

After 6 h of fasting, mice were subjected to i.p. injection of insulin (0.5 mU/g body weight), followed by blood glucose measurement at multiple time points.

Inverse PCR

The strategy of IPCR was described previously (Li *et al.* 1999). Genomic DNA was prepared from mouse tail biopsy with the previously described procedure (Laird *et al.* 1991). Genomic DNA (5 µg) was digested with 40 U restriction endonuclease *StuI* (New England Biolabs, Ipswich, MA, USA) in a total volume of 50 µl (37 °C, overnight). Following inactivation of the restriction enzyme (65 °C, 20 min) and precipitation in 70% ethanol, the restrictive DNA fragments were ligated with 3200 U of T4 DNA ligase (New England Biolabs) in a total volume of 450 µl (16 °C, overnight) to form circles. After precipitation in 70% ethanol, the DNA was dissolved in 40 µl storage buffer (10 mM Tris-Cl, 0.1 mM EDTA, pH 7.5) and served as the template of the subsequent nested PCR. The nested PCR was performed in a total volume of 50 µl, with 2.5 U Taq polymerase (New England Biolabs) and 2.5 U Taq extender (Stratagene, La Jolla, CA, USA). The primer sequences are listed in Table 1. PCR products were separated by agarose gel electrophoresis, purified with Gel Extraction Kit (Qiagen), and sequenced.

Genotyping

The D2 transgenic mouse lines (D2D, D2P, and D2L) were genotyped by PCR with the primer pair LacZ-901 and LacZ-1351, yielding a 451 bp product from the D2/LacZ transgene locus and no product from the wild-type allele. For direct determination of the junction sequences between genomic DNA and the transgene, the primers G78P-1R and *ItpR* were used for the 5'-end, and M106M-f6 and LacZ-3F for the 3'-end. To distinguish the homozygous *D2D* mice from the heterozygous mice, PCR primers *ItpR*-1f and *ItpR*-3 were used to amplify a 604 bp product exclusively from the wild-type allele, whereas LacZ-901 and LacZ-1351 were used to detect the *D2D* allele. The primer sequences are listed in Table 2. *Opt* mice were genotyped following the protocol from the Jackson Laboratory.

Table 1 Primers for inverse PCR (IPCR)

For the 5'-end of the D2/LacZ transgene	
First pair	
G78P-1F	5'-GCAGCGTACTTCTCCGAGTGAGA-3'
G78P-1R	5'-TCACAAAGATTGCTCTGCTTCTATCT-3'
Second pair	
G78P-2F	5'-GAAACGGTTTCCAGGTGAGAGGTCA-3'
G78P-2R2	5'-CATGAGCCACCATATCTATCTCCT-3'
For the 3'-end of the D2/LacZ transgene	
First pair	
LacZ-1F	5'-CGCTACAGTCAACAGCAACTGATGGA-3'
LacZ-1R	5'-CTGCAAGGCGATTAAGTTGGGTAAC-3'
Second pair	
LacZ-2F	5'-CATGGCTGAATATCGACGGTTTCCA-3'
LacZ-2R	5'-CGGCTTACGGCAATAATGCCTTTCCA-3'

Table 2 Primers for mouse genotyping

LacZ-901	5'-CTGGCTGGAGTGGCATCTTCTGAG-3'
LacZ-1351	5'-GCGAGTGGCAACATGGAAATCGCTG-3'
G78P-1R	5'-TCACAAAGATTGCTCTGCTTCTATCT-3'
<i>ItpR</i>	5'-AGGAGGCCATCCCAAGAGGCACGAT-3'
M106M-f6	5'-CAGAGTATGTTTCTGTTCTTGCCCTGATGG-3'
LacZ-3F	5'-GACAAACTCGGAACTTGTATTGTCAGC-3'
<i>ItpR</i> -1f	5'-TTCATCTGGTTCGTAGTTGCGTGG-3'
<i>ItpR</i> -3	5'-CACAGATGGCCTGGCTAGAAAACAGAGG-3'

Immunoblotting

Whole cell lysates of mouse tissues were prepared as described (Ye *et al.* 2010a). To detect IP3R isoforms with high molecular weight (more than 240 kDa), protein lysates were separated on 6% SDS-PAGE. The IP3R antiserum and antibody were obtained from Dr Richard Wojcikiewicz (State University of New York Upstate Medical University). These included rabbit polyclonal IP3R1 (CT1) antiserum against the conserved C terminus of rat IP3R1, rat monoclonal IP3R1 (4C11) antibody against the amino acids 679–727 of mouse IP3R1. β-actin primary antibody was from Sigma–Aldrich.

Immunohistochemistry

Mouse pancreas was dissected and fixed in 10% PBS-buffered formalin, then processed for paraffin sections. Immunostaining was performed as described previously (Ye *et al.* 2010b). Primary antibodies used included insulin and glucagon (Signet Labs, Dedham, MA, USA). Quantitation of insulin-positive β-cell area and insulin staining density was performed on multiple sections with ImageJ 1.40 Software (National Institutes of Health, Bethesda, MD, USA).

Islet insulin content

After anesthesia and killing, mouse islets of Langerhans were prepared as described previously (Ye *et al.* 2010b). Briefly, about 3.5 ml ice-cold digestion solution, which consisted of 0.233 mg/ml Liberase RI and 0.1 mg/ml DNase (Roche) in Hanks' balanced salt solution (HBSS), was infused into the pancreas via the common bile duct and the pancreatic duct. The inflated pancreas was excised and transferred to a glass vial with 2.5 ml ice-cold digestion solution. After incubation in a 37 °C water bath for 25 min, the vial was shaken by hand vigorously for 45 s to disperse the digested content. After washing with ice-cold HBSS at least five times, the content was placed in a 10 cm dish, and the islets were hand-picked under a microscope. Individual islet was disrupted in 0.2 ml of 1 M acetic acid with 0.1% BSA and protease inhibitor cocktail (Roche) by sonication (30 s, on ice). Islet lysates were 1:200 diluted and assayed for insulin concentration with ELISA kit (Linco Research).

Statistical analysis

Two-tailed student's *t*-test was applied for all pairwise comparisons.

Results

Impaired glucose homeostasis in *D2D* transgenic mice

Toward understanding how *Grp78* transcription is regulated *in vivo*, *D2*, an internal deletion mutant of the 3 kb rat *Grp78* promoter, was constructed to drive an *LacZ* reporter gene (Fig. 1A). Within the *D2* promoter, the sequence spanning -300 to -170 was deleted, eliminating the ATF/CRE-like site and adjacent upstream sequence. In total, three lines of the *D2* transgenic mice were independently generated, denominated as *D2D*, *D2P*, and *D2L*. Serendipitously, we observed elevated fasting blood glucose in male *D2D* mice (136 ± 14 vs 105 ± 6 mg/dl in their sex-matched wild-type littermates, $P=0.048$) at the age of 22 weeks (Fig. 1B), but not in the *D2P* (Fig. 1C) or *D2L* (data not shown) lines. This moderate hyperglycemia was not due to excessive food intake (Fig. 1D). Rather, it associated with a 45% decrease in blood insulin (Fig. 1E). Strikingly, *D2D* mice developed progressive glucose intolerance, from 14 week old (Fig. 1F) to 23 week old (Fig. 1G), as revealed by intraperitoneal glucose tolerance test.

Disruption of the *IP3R 1*-encoding gene (*Itpr1*) in *D2D* mice

Our observation that perturbed glucose homeostasis was only observed in the *D2D* line but not in the other lines of the *D2* transgenic mice suggests that it likely resulted from the genomic integration site of the *D2* transgene in the *D2D* line rather than an inherent property of the *D2* transgene. To identify the genomic DNA sequences flanking the transgene in the *D2D* mice, we employed the IPCR strategy described previously (Li *et al.* 1999). As depicted in Fig. 2A, the genomic DNA from the *D2D* mice was digested with the restriction endonuclease *StuI*, which cut the *D2/LacZ* transgene once in the middle. Following the circular ligation of the restricted DNA fragments, the genomic DNA flanking the 5'-end (Fig. 2B) and 3'-end (Fig. 2C) of the transgene was amplified by nested PCR. Sequencing of the nested PCR products revealed that the two loci flanking the *D2* transgene were located on mouse chromosome 6 and identified as the *Itpr1* and *Cntn4* (contactin 4; Cottrell *et al.* 2011) genes (Fig. 2D). In addition, a 2.4 kb upstream fragment on chromosome 6 was incorporated between the 5'-end of the transgene and the 3'-half of the *Itpr1* locus, in a reverse complementary manner. The nested PCR also amplified sequences from the self-ligated transgene, suggesting the presence of tandem repeats of the transgene in the genome. The junctions between the transgene and the mouse genome were independently determined by PCR amplification from




Figure 1 *D2D* transgenic mice exhibited progressive impairment of glucose homeostasis. Schematic drawing of the 3 kb *LacZ* and *D2/LacZ* reporter genes. The locations of the TATA box, ERSE, and the CRE element are indicated. Additional CCAAT sequences and their orientation with respect to the TATA element are represented by arrows. The lollipop symbols indicate the occurrence of GC-rich sequences similar to Sp1 binding sites (A). Fasting blood glucose of *D2D* mice and their wild-type (WT) siblings at the indicated ages ($n \geq 7$ mice for each genotype) (B). Fasting blood glucose of 7-month-old WT ($n=5$) and *D2P* mice ($n=7$) (C). Food intake measurement on 7-month-old WT and *D2D* mice ($n=3$ per genotype) (D). Fasting blood insulin of 6-month-old WT ($n=14$) and *D2D* mice ($n=12$) (E). Glucose tolerance test on 14-week-old WT ($n=6$) and *D2D* ($n=5$) mice (F). Glucose tolerance test on 23-week-old WT ($n=6$) and *D2D* ($n=7$) mice (G). Data are presented as the mean \pm S.E.M. * $P < 0.05$, ** $P < 0.01$.




Figure 2 Identification of the genomic DNA sequences flanking the transgene in *D2D* mice. Strategy of the inverse PCR (IPCR). The *D2/LacZ* transgene is presented with 5′–3′ orientation. The single *Stul* restriction site on the transgene is indicated by a solid line, with the assumed ones on the flanking genomic DNA represented by dashed lines. The restrictive DNA fragments were ligated to form circles. The position and orientation of the nested PCR primers are indicated by arrows underneath the transgene, for detection of the genomic sequences flanking either the 5′-end or the 3′-end of the transgene (A). Agarose gel electrophoresis of the products from the nested PCR. Asterisks indicate the PCR products containing mouse genomic DNA, flanking the 5′-end (B) or the 3′-end (C) of the transgene, as revealed by sequencing and BLAST with assembled mouse genome. Schematic drawing of the transgene tandem repeats with flanking genomic sequences on mouse chromosome 6, as suggested by IPCR. The gray boxes represent the genomic DNA, with arrows above indicating their 5′–3′ orientation on the chromosome 6. Their positions on the chromosome and the involved loci are also noted on top. The *Stul* sites on the transgene repeats and the flanking DNA are labeled (D). To independently determine the junction sequences, the primer pair M106M-f6 and LacZ-3F was used for the 3′-end of the transgene, yielding a 0.54 kb PCR product (E) and the G78P-1R and *ItpR* pair was used for the 5′-end, yielding a 5.0 kb PCR product (F).

the *D2D* genomic DNA and sequencing of the PCR products (Fig. 2E and F), providing direct evidence that the *Cntn4* and *Itp1* genes were interrupted in the *D2D* mice.

Genomic mapping by IPCR implied that on chromosome 6 of the *D2D* mice, the 2.4 Mbp genomic DNA between the two junctions was replaced by the tandem repeats of *D2/LacZ* transgene, with its 5′–3′ orientation in inverse to that of chromosome 6 (Fig. 3A). The 2.4 Mbp sequences contain

eight intact loci, as well as the 3′-half of *Cntn4* and the 5′-half of *Itp1* (Fig. 3B). The identification of the junction sequences enabled us to distinguish the homozygous *D2D* (*D/D*) from the heterozygous mice (*D/+*) by determining the presence of the wild-type allele (+) and the *D2D* allele (*D*) with genotyping via PCR. In 3-week-old offspring ($n=52$) from *D/+* × *D/+* mating pairs, there was no *D/D*, and the $+/+ : D/+$ ratio was approximate to 1:2 (Fig. 3C). The lethality for the homozygous *D2D* mice was consistent with that reported for the homozygous *Itp1* knockout and *opt* mutant mice (Matsumoto *et al.* 1996, Street *et al.* 1997). However, the contribution by the other nine disrupted loci remains to be determined. In agreement with the genetic and molecular data that the *D2D* mice were heterozygous for the transgene insertion (*D/+*), the level of the *Itp1*-encoded IP3R1 protein in *D2D* mouse brain was reduced by about 63% compared with wild-type siblings, as revealed independently in western blots using antibodies against the amino acids 679–727 (4C11) or the carboxyl end (CT1) of IP3R1 (Fig. 3D). In contrast to its prominent expression in the brain, IP3R1 protein was barely detectable in the liver and below detection limit in white adipose and spleen of both wild-type and *D2D* mice (Fig. 3E).

Perturbed glucose homeostasis in the Itp1 heterozygous mutant (opt/+) mice

IP3R1 is the most abundant isoform in mouse neurons, serving critical functional roles (Foskett 2010). It is also highly expressed in pancreatic β -cells together with IP3R3 (De Smedt *et al.* 1997, Lee & Laychock 2001), with implied function in Ca^{2+} signaling and exocytosis (Dyachok & Gylfe 2004, Dyachok *et al.* 2004). As both central nervous system and endocrine pancreas are essential for glucose homeostasis and energy metabolism (Prentki & Nolan 2006, Cota *et al.* 2007), we directly examined the role of IP3R1 in glucose metabolism using the *opt/+* mouse model, which had been established to express reduced level of IP3R1 (Street *et al.* 1997). Only male mice were used for examination, because the hormonal cycle in females might interfere with metabolism and complicate the results. During the age of 10–18 weeks, the fasting body weight (Fig. 4A) and blood glucose (Fig. 4B) of *opt/+* mice were similar to those of their wild-type littermates. The weight of epididymal fat pads and liver were similar between the two genotypes (Fig. 4C). Analysis of serum levels of triglycerides (Fig. 4D) and free fatty acids (Fig. 4E) showed trends toward elevation in *opt/+* mice, although neither of them reached statistical significance at the sample size being examined. However, at the age of 10 weeks, *opt/+* mice exhibited overt glucose intolerance (Fig. 4F). During the intraperitoneal glucose tolerance test, *opt/+* mice reached a higher level of blood glucose than wild-type (260 ± 10 vs 206 ± 10 mg/dl, $P=0.009$) 15 min after an injection of glucose (1 mg/g body weight). While the blood glucose level in wild type (105 ± 3 mg/dl) was restored to the fasting level 2 h after the glucose bolus, the blood




Figure 3 *D2D* mice are *Itp1* heterozygous. Schematic drawing of *D2D* mouse chromosome 6 with the transgene insert. In the 148 Mbp of mouse chromosome 6 (upper panel), the area surrounding the transgene insertion site is represented by the gray box expanded in the lower panel. Schematic drawing of the insertion site was modified from the MGI Mouse Genome Browser on build 37, NCBI transcripts. The transgene in reverse complementary tandem repeats (solid arrows) displaces a 2.4 Mbp (106.0–108.4 Mbp) segment of genomic DNA (A). The ten open reading frames in this segment are represented by the numbered open arrows underneath and annotated in (B). The arrows indicate the orientation of the genes. Genotypes of 3-week-old offspring from mating pairs of heterozygous *D2D* mice ($D/+ \times D/+$) with observed numbers. (*Probability of finding no homozygous *D2D* (*D/D*) progeny among 52 individuals by chance; $P=3.2 \times 10^{-7}$) (C). Western blotting for IP3R1 in the brain of *D2D* mice and their wild-type (WT) littermates (D). Primary antibodies against amino acids 679–727 (4C11) or the conserved C terminal (CT1) of IP3R1 were used. β-actin served as the loading control. Western blotting for IP3R1 in the brain, liver, white adipose and spleen of WT and *D2D* mice, with β-actin as the loading control (E).

glucose level in the *opt/+* mice (138 ± 7 mg/dl) remained significantly higher ($P=0.003$). The defective glucose clearance in *opt/+* mice was not a likely outcome of insulin resistance, because the whole body insulin sensitivity was similar between the two genotypes, as revealed by the intraperitoneal insulin tolerance test (Fig. 4G).

To investigate whether defective insulin production contributes to the glucose intolerance, we first measured the fasting insulin (Fig. 5A) and observed a 17% decrease in *opt/+* mice (29 ± 3 vs 24 ± 2 pM in wild type, $P=0.17$). After a bolus of glucose stimulation via i.p. injection, while the wild types exhibited a biphasic insulin response in blood, *opt/+* mice showed an intact first phase followed by a significantly diminished second phase (Fig. 5B). Immunostaining on pancreas sections revealed decreased β-cell mass and insulin content in *opt/+* mice (Fig. 5C). In contrast, the α-cell distribution was comparable to wild type (Fig. 5D). Quantitative analysis confirmed lower β-cell area (Fig. 5E) and insulin staining density (Fig. 5F) in *opt/+* mice. To directly examine the islet insulin content, we freshly isolated pancreatic islets from $+/+$ and *opt/+* mice and selected for size-matched ones via microscopy. A 16% decrease in the average insulin content was observed in *opt/+* islets compared with wild type (Fig. 5G), which is consistent with the immunohistochemistry quantitation (Fig. 5F). Collectively, these data suggest defective insulin production

in *opt/+* mice, which could contribute in part to the glucose intolerance.

Susceptibility to diet-induced diabetes in *opt/+* mice

To test whether *Itp1* heterozygosity exposes the mice to diet-induced diabetes, we fed cohorts of *opt/+* mice and their wild-type littermates with HFD from 10 week old (Fig. 6A). The *opt/+* mice showed about 90% of food intake as their wild-type siblings (Fig. 6B), and no fat mal-absorption as revealed by Oil Red O staining of stool smear (Fig. 6C).

During the first 6 weeks of HFD regimen, the body weight gain was similar between the two genotypes (Fig. 7A). However, *opt/+* mice showed a rapid increase in fasting blood glucose from the fourth week of HFD (139 ± 6 vs 113 ± 3 mg/dl in wild type, $P=0.0005$; Fig. 7B). Hyperglycemia remained evident in *opt/+* mice after 6 weeks of HFD (148 ± 7 vs 122 ± 6 mg/dl in wild type, $P=0.008$; Fig. 7B). Correspondingly, exacerbated glucose intolerance was observed in *opt/+* mice after 4 weeks of HFD (Fig. 7C). As further evidence of perturbed glucose metabolism, *opt/+* mice were more insulin resistant than wild type, as revealed by the intraperitoneal insulin tolerance test after 6 weeks of HFD (Fig. 7D). Taken together, our results suggest that the glucose homeostasis in *opt/+* mice was more vulnerable on HFD challenge. With reduced IP3R1 protein expression, *opt/+* mice were predisposed to HFD-induced diabetes.




Figure 4 Glucose intolerance in *opt/+* mice. Fasting body weight (A) and fasting blood glucose (B) of *opt/+* mice and their wild-type littermates (+/+), $n \geq 6$ mice per genotype. Epididymal fat pad and liver weight normalized against whole body weight, $n = 7$ (+/+) or 6 (*opt/+*) (C). Serum concentration of triglyceride (D) and free fatty acid (E), $n = 4$ (+/+) or 5 (*opt/+*). Glucose tolerance test on 10-week-old mice, $n = 6$ (+/+) or 8 (*opt/+*) (F). Insulin tolerance test on 11-week-old mice, $n = 12$ (+/+) or 15 (*opt/+*). For an individual mouse, the blood glucose level is calculated as percentage of that at 0 min (G). Data are presented as the mean \pm S.E.M. * $P < 0.05$, ** $P < 0.01$.

Discussion

The *D2D* transgenic mouse line was originally constructed for the study of *Grp78* promoter analysis. Unexpectedly, *D2D* mice exhibit progressive glucose intolerance not seen in other independently derived lines from the same transgene. This led to the discovery that the *D2/LacZ* transgene has serendipitously inserted into mouse chromosome 6 and along with displacement of several other loci, split *Itp1* into half. Considering that IP3R1 is both a receptor for IP3 and a calcium channel, generation of viable mouse models with mutated IP3R1 function provides a valuable tool for the

understanding of its function *in vivo*. However, as the *D2D* harbors other chromosomal aberrations in addition to *Itp1* disruption, it is not possible to dissect the contribution of *Itp1* from the other perturbed loci.

Mouse models targeting *Itp1* function have previously been reported including the *Itp1* knockout model (Matsumoto *et al.* 1996) and the *opt* mutant mouse model (Street *et al.* 1997). While the former is not available, the *opt/+* mutant mice with an altered *Itp1* gene are commercially available and aptly serve as a surrogate for the *D2D* transgenic line with a single disruption of the *Itp1* locus. Previous studies on IP3R1 have focused on its regulation of calcium channels in relationship to neurological function. For example, both the *opt* (Street *et al.* 1997) and more recently the $\Delta 18$ mice (van de Leemput *et al.* 2007) bearing spontaneous mutation of the *Itp1* gene led to neuronal dysfunction. The fact that homozygous deletion of the *Itp1*




Figure 5 Reduced pancreatic β -cell mass and insulin content in *opt/+* mice. For 10-week-old *opt/+* mice and their wild-type littermates (+/+): fasting blood insulin, $n = 9$ mice per genotype (A). Blood insulin during glucose tolerance test, $n = 6$ mice per genotype (B). Immunostaining of insulin (C) and glucagon (D) on pancreas, $n = 5$ (+/+) or 6 (*opt/+*). Lower panels demonstrate enlarged view of the boxed area in the corresponding upper panels. Quantitation of the β -cell area (E) and brown staining density (F) of the insulin-stained cells. Brown areas are normalized against the corresponding whole pancreas section areas. Insulin content in size-matched isolated islets, $n = 13$ per genotype (G). Data are presented as the mean \pm S.E.M. * $P < 0.05$, ** $P < 0.01$. Full colour version of this figure available via <http://dx.doi.org/10.1530/JOE-11-0012>.




Figure 6 HFD-fed *opt/+* mice showed normal food intake and fat absorption. Scheme of high-fat diet (HFD) feeding. Cohorts of *opt/+* and *+/+* male littermates were fed regular diet (RD) after being weaned at 3 week old and switched to HFD feeding from 10 week old (A). For mice during the fifth week of HFD. Food intake measurement, $n=6$ for each genotype. Data are presented as the mean \pm S.E.M. (B). Oil Red O staining of stool smear. Negative control: dH₂O; positive control: white adipose extract, $n=4$ for each genotype (C).

alleles in mice results in ataxia and seizure followed by death by a few weeks after birth did not lend itself to studies on its function in metabolic diseases, which require the mice to reach adulthood in relatively stable health. As the *opt/+* mice are phenotypically normal, their potential defects in metabolism have not been apparent in past studies.

On matching the *D2D* mice with the *opt/+* mice, our studies extend characterization of the *opt/+* mice and reveal several new findings on IP3R1 function in regulation of glucose homeostasis. First, in mouse peripheral tissues including liver and white adipose, IP3R1 protein is hardly detectable by immunoblotting, in agreement with the previous report on its tissue-specific mRNA expression (De Smedt *et al.* 1997). Consistent with this notion, insulin sensitivity is not altered in regular diet-fed *opt/+* mice compared with wild type, rendering it unlikely that reduced IP3R1 suppresses insulin-stimulated glucose metabolism in peripheral tissues. Importantly, reduction of IP3R1 in *opt/+* mice leads to impaired glucose tolerance, correlating with the observations in *D2D* mice. Although the underlying mechanisms could be complex involving multiple pathways in different organs, our *in vivo* and *in vitro* data support the notion that *Itp1* heterozygosity reduces both the mass and the insulin production of pancreatic β -cells. These could synergistically contribute to the attenuation of second-phase glucose-stimulated insulin response in *opt/+* mice. Considering that IP3R1 is the dominant isoform expressed in the mouse central nervous system that regulates satiety and neuronal regulated

insulin secretion (Foskett 2010), it is also tempting to speculate that the glucose intolerance in *opt/+* mice could be the functional defect in neurons responsible for nutrient sensing and glucose regulation (Cota *et al.* 2007). Another possibility could relate to the emerging role of IP3Rs in regulation of cytosolic Ca²⁺ and thus insulin secretion in pancreatic β -cells (Srivastava *et al.* 1999, Dyachok & Gylfe 2004), where IP3R1 is also highly expressed (Lee & Laychock 2001). The resolution of these issues awaits further investigation such as comprehensive characterization of insulin sensitivity in individual organs (Kim 2009) and may be best addressed in future studies using mouse models with tissue-specific ablation of IP3R1.

Our studies demonstrate that on HFD, the requirement of IP3R1 to maintain glucose homeostasis is more acute. Unlike mice on regular diet, these mice develop hyperglycemia, severe glucose intolerance, and insulin resistance, suggesting predisposition to diabetes. In support of our findings, it was recently reported that parasympathetic stimulation of pancreatic islets augments glucose-stimulated insulin secretion by inducing IP3R-mediated Ca²⁺ release, such that defective glycaemic regulation through loss of ankyrin-B-dependent stabilization of IP3R is a potential risk factor for type 2 diabetes (Healy *et al.* 2010). Future studies on the molecular pathways leading to development of diabetes due to IP3R deficiency may provide novel strategies to combat diet- and age-onset diabetes.




Figure 7 *Opt/+* mice were predisposed to HFD-induced diabetes. Fasting body weight (A) and fasting blood glucose (B) of mice fed high-fat diet (HFD) from 10 week old, $n \geq 8$ mice per genotype. Glucose tolerance test on mice after 4-week HFD, $n=9$ (*+/+*) or 7 (*opt/+*) (C). Insulin tolerance test on mice after 6-week HFD, $n=10$ (*+/+*) or 4 (*opt/+*) (D). Data are presented as the mean \pm S.E.M. * $P < 0.05$, ** $P < 0.01$.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research was supported by grants from the National Institutes of Health R01CA027607, R01DK070582, and R01DK079999 awarded to A S L, and R01DK060623 and R01GM085791 to R H C.

Acknowledgements

We thank Dr Richard Wojcikiewicz for the generous gift of antibodies. We thank the Richard Bergman laboratory for expert assistance in insulin assays and helpful discussion. We thank the USC Norris Comprehensive Cancer Center Transgenic/Knockout Mouse Core for generation of the transgenic mice and the Molecular Genomics Core for DNA sequencing. The described USC core facilities were supported in part by P30CA014089 from the National Cancer Institute. We also thank Dr Philipp Scherer and the Mouse Metabolic Phenotyping Core at University of Texas Southwestern Medical Center for assistance in triglyceride and free fatty acid assays.

References

- Cota D, Proulx K & Seeley RJ 2007 The role of CNS fuel sensing in energy and glucose regulation. *Gastroenterology* **132** 2158–2168. (doi:10.1053/j.gastro.2007.03.049)
- Cottrell CE, Bir N, Varga E, Alvarez CE, Bouyain S, Zernzach R, Thrush DL, Evans J, Trimarchi M, Butter EM *et al.* 2011 Contactin 4 as an autism susceptibility locus. *Autism Research* **4** 189–199. (doi:10.1002/aur.184)
- De Smedt H, Missiaen L, Parys JB, Henning RH, Sienaert I, Vanlingen S, Gijssens A, Himpens B & Casteels R 1997 Isoform diversity of the inositol trisphosphate receptor in cell types of mouse origin. *Biochemical Journal* **322** 575–583.
- Dong D, Dubeau L, Bading J, Nguyen K, Luna M, Yu H, Gazit-Bornstein G, Gordon EM, Gomer C, Hall FL *et al.* 2004 Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors. *Human Gene Therapy* **15** 553–561. (doi:10.1089/104303404323142006)
- Dyachok O & Gylfe E 2004 Ca(2+)-induced Ca(2+) release via inositol 1,4,5-trisphosphate receptors is amplified by protein kinase A and triggers exocytosis in pancreatic beta-cells. *Journal of Biological Chemistry* **279** 45455–45461. (doi:10.1074/jbc.M407673200)
- Dyachok O, Tufveson G & Gylfe E 2004 Ca²⁺-induced Ca²⁺ release by activation of inositol 1,4,5-trisphosphate receptors in primary pancreatic beta-cells. *Cell Calcium* **36** 1–9. (doi:10.1016/j.ceca.2003.11.004)
- Foskett JK 2010 Inositol trisphosphate receptor Ca²⁺ release channels in neurological diseases. *Pflügers Archiv: European Journal of Physiology* **460** 481–494. (doi:10.1007/s00424-010-0826-0)
- Foskett JK, White C, Cheung KH & Mak DO 2007 Inositol trisphosphate receptor Ca²⁺ release channels. *Physiological Reviews* **87** 593–658. (doi:10.1152/physrev.00035.2006)
- Futatsugi A, Nakamura T, Yamada MK, Ebisui E, Nakamura K, Uchida K, Kitaguchi T, Takahashi-Iwanaga H, Noda T, Aruga J *et al.* 2005 IP3 receptor types 2 and 3 mediate exocrine secretion underlying energy metabolism. *Science* **309** 2232–2234. (doi:10.1126/science.1114110)
- Healy JA, Nilsson KR, Hohmeier HE, Berglund J, Davis J, Hoffman J, Kohler M, Li LS, Berggren PO, Newgard CB *et al.* 2010 Cholinergic augmentation of insulin release requires ankyrin-B. *Science Signaling* **3** ra19. (doi:10.1126/scisignal.2000771)
- Kim JK 2009 Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity *in vivo*. *Methods in Molecular Biology* **560** 221–238. (doi:10.1007/978-1-59745-448-3_15)

- Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R & Berns A 1991 Simplified mammalian DNA isolation procedure. *Nucleic Acids Research* **19** 4293. (doi:10.1093/nar/19.15.4293)
- Lee B & Laychock SG 2001 Inositol 1,4,5-trisphosphate receptor isoform expression in mouse pancreatic islets: effects of carbachol. *Biochemical Pharmacology* **61** 327–336. (doi:10.1016/S0006-2952(00)00559-1)
- van de Leemput J, Chandran J, Knight MA, Holtzclaw LA, Scholz S, Cookson MR, Houlden H, Gwinn-Hardy K, Fung HC, Lin X *et al.* 2007 Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. *PLoS Genetics* **3** e108. (doi:10.1371/journal.pgen.0030108)
- Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada DA, Nakamura T, Shaughnessy JD Jr, Jenkins NA & Copeland NG 1999 Leukaemia disease genes: large-scale cloning and pathway predictions. *Nature Genetics* **23** 348–353. (doi:10.1038/15531)
- Luo S, Baumeister P, Yang S, Abcouwer SF & Lee AS 2003 Induction of Grp78/BiP by translational block: activation of the Grp78 promoter by ATF4 through an upstream ATF/CRE site independent of the endoplasmic reticulum stress elements. *Journal of Biological Chemistry* **278** 37375–37385. (doi:10.1074/jbc.M303619200)
- Matsumoto M, Nakagawa T, Inoue T, Nagata E, Tanaka K, Takano H, Minowa O, Kuno J, Sakakibara S, Yamada M *et al.* 1996 Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor. *Nature* **379** 168–171. (doi:10.1038/379168a0)
- Prentki M & Nolan CJ 2006 Islet beta cell failure in type 2 diabetes. *Journal of Clinical Investigation* **116** 1802–1812. (doi:10.1172/JCI29103)
- Roach JC, Deutsch K, Li S, Siegel AF, Bekris LM, Einhaus DC, Sheridan CM, Glusman G, Hood L, Lernmark A *et al.* 2006 Genetic mapping at 3-kilobase resolution reveals inositol 1,4,5-trisphosphate receptor 3 as a risk factor for type 1 diabetes in Sweden. *American Journal of Human Genetics* **79** 614–627. (doi:10.1086/507876)
- Srivastava M, Atwater I, Glasman M, Leighton X, Goping G, Caohuy H, Miller G, Pichel J, Westphal H, Mears D *et al.* 1999 Defects in inositol 1,4,5-trisphosphate receptor expression, Ca(2+) signaling, and insulin secretion in the anx7(+/-) knockout mouse. *PNAS* **96** 13783–13788. (doi:10.1073/pnas.96.24.13783)
- Street VA, Bosma MM, Demas VP, Regan MR, Lin DD, Robinson LC, Agnew WS & Tempel BL 1997 The type 1 inositol 1,4,5-trisphosphate receptor gene is altered in the opisthotonos mouse. *Journal of Neuroscience* **17** 635–645.
- Taylor CW, Taufiq-Ur-Rahman & Pantazaka E 2009 Targeting and clustering of IP3 receptors: key determinants of spatially organized Ca²⁺ signals. *Chaos* **19** 037102. (doi:10.1063/1.3127593)
- Vanderheyden V, Devogelaere B, Missiaen L, De Smedt H, Bultynck G & Parys JB 2009 Regulation of inositol 1,4,5-trisphosphate-induced Ca²⁺ release by reversible phosphorylation and dephosphorylation. *Biochimica et Biophysica Acta* **1793** 959–970. (doi:10.1016/j.bbamer.2008.12.003)
- Wang M, Wey S, Zhang Y, Ye R & Lee AS 2009 Role of the unfolded protein response regulator Grp78/BiP in development, cancer, and neurological disorders. *Antioxidants and Redox Signaling* **11** 2307–2316. (doi:10.1089/ars.2009.2485)
- Xian M, Zhang J & Lau YF 2001 Sry promoters from domestic (Tirano) and C57BL/6 mice function similarly in embryos and adult animals. *Journal of Experimental Zoology* **290** 632–641. (doi:10.1002/jez.1114)
- Ye R, Jung DY, Jun JY, Li J, Luo S, Ko HJ, Kim JK & Lee AS 2010a Grp78 heterozygosity promotes adaptive unfolded protein response and attenuates diet-induced obesity and insulin resistance. *Diabetes* **59** 6–16. (doi:10.2337/db09-0755)
- Ye R, Mareninova OA, Barron E, Wang M, Hinton DR, Pandol SJ & Lee AS 2010b Grp78 heterozygosity regulates chaperone balance in exocrine pancreas with differential response to cerulein-induced acute pancreatitis. *American Journal of Pathology* **177** 2827–2836. (doi:10.2353/ajpath.2010.100368)

Received in final form 13 April 2011

Accepted 12 May 2011

Made available online as an Accepted

Preprint 12 May 2011